γ-Hydroxybutyric Acid: A GABAB/GHB Receptor Agonist with a Unique Neuropharmacological and Therapeutic Profile

Bavato, Francesco

doi:10.1007/978-3-031-67148-7_13

The Receptors

2024

DOI: 10.1007/978-3-031-67148-7_13

|View full text |Cite

γ-Hydroxybutyric Acid: A GABAB/GHB Receptor Agonist with a Unique Neuropharmacological and Therapeutic Profile

Francesco Bavato

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial

Bavato,

Schnider,

Dornbierer

et al. 2024

Preprint

View full text Add to dashboard Cite

In major depressive disorder (MDD), main clinical features include insomnia and increased daytime sleepiness. However, specific treatment options to promote sleep in MDD are limited. Gamma-hydroxybutyrate (GHB, clinically administered as sodium oxybate) is a GHB/GABAB receptor agonist used clinically in narcolepsy, where it promotes restorative slow-wave sleep (SWS) while reducing next-day sleepiness. Therefore, we performed a randomized, placebo- and active comparator-controlled, double-blind, crossover trial to investigate the sleep-promoting properties of GHB in individuals with MDD. Outpatients aged 20-65 years fulfilling the DSM-V criteria for MDD were enrolled. A single dose of GHB (50mg/kg) was compared with a single dose of the clinical competitor trazodone (1.5 mg/kg) and placebo. Of 29 randomized patients, 23 received at least one intervention and were included in the analysis. Primary outcomes were slow wave sleep ([SWS], as % of total sleep time [TST]) assessed by polysomnography and next-day vigilance (median response time and number of lapses in the psychomotor vigilance test [PVT]). GHB robustly prolonged SWS compared to both trazodone and placebo. GHB also prolonged TST and enhanced sleep efficiency (TST % of time-in-bed), while reducing sleep stages N1, N2, and wake-after-sleep-onset. While the median response time on the PVT was unaffected, GHB reduced the number of lapses compared to trazodone and placebo. No serious adverse events occurred. A single nocturnal dose of GHB effectively promotes SWS and shows more favorable effects on next-day vigilance than trazodone and placebo. Future studies should investigate GHB in clinical settings, including repeated administration.

show abstract

Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial

Bavato,

Schnider,

Dornbierer

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

γ-Hydroxybutyric Acid: A GABAB/GHB Receptor Agonist with a Unique Neuropharmacological and Therapeutic Profile

Cited by 1 publication

References 117 publications

Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial

Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial

Contact Info

Product

Resources

About